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Copyright © 2008 JCBN Summary Proton pump inhibitors (PPIs) are now commonly used for the treatment of acid
related diseases such as peptic ulcer and reflux esophagitis. Because of their ability to produce
direct inhibition of the proton pump, PPIs provide more sustained increase of the gastric pH
than H2-receptor (H2R) antagonists. Diverse reports have been published on gastric epithelial
cell modality associated with PPI treatment both in animal models and clinical settings. The
present review summarizes the recent accumulated evidence on gastric epithelial cell modality
associated with PPI treatment, including the formation of gastric carcinoid tumors and fundic
gland polyps, and the development of gastric mucosal atrophy. Long-term PPI treatment has
been reported to cause enlargement of the parietal cells and enterochromaffin-like cells, and
to decrease the number of chief cells without affecting A-like cell. Although the development
of gastric carcinoid tumors after chronic PPI treatment has been reported in animal studies,
no such occurrences have been demonstrated in humans. The effect of PPIs on the formation
of fundic gland polyps and the development of atrophic gastritis should be investigated in
future studies.
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Introduction
Gastric acid in the stomach facilitates the digestion of
protein and also protects against bacterial overgrowth and
enteric infections. Gastric acid secretion is stimulated by
histamine, gastrin or acetylcholine, mediated via the basolat-
eral surface receptors on the parietal cells. Proton pump in-
hibitors (PPIs) inhibit H+, K+-adenosine triphosphatase (H+,
K+-ATPase) in the parietal cells, which is involved in the
final step of gastric acid secretion. The enzyme is composed
of two subunits, a 114-kDa alpha-subunit and a 35-kDa beta-
subunit [1, 2]. PPIs are converted to tetracyclic sulfonamides
which bind with the cysteine residues in the alpha subunit of
the gastric H+, K+-ATPase. Besancon et al. reported that the
common binding sites of PPIs is the cysteine residue at
position 813 in the alpha subunit of the gastric H+, K+-
ATPase (Fig. 1) [3]. As well as gastric parietal cells,
Nakamura et al. reported PPI uptake sites have been seen in
Helicobacter pylori ( H. pylori), colonic epithelial cells,
inflammatory cells, peripheral autonomic nerves and ECL
cells [4].
Since PPIs produce histamine, gastrin or acetylcholine-
independent inhibition of acid secretion, they provide moreT. Masaoka et al.
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sustained increase of the gastric pH than H2-receptor (H2R)
antagonists [5]. In Japan, lansoprazole, omeprazole and
rabeprazole are officially approved for the treatment of
peptic ulcer disease, gastro-esophageal reflux disease
(GERD) and H. pylori infection.
The gastric fundic glands are composed of several types
of epithelial cells, such as pit cells, mucous-neck cells, chief
cells, parietal cells, and endocrine cells such as entero-
chromaffin-like (ECL) cells, A-like cells, somatostatin-
producing D cells and gastrin producing G cells (Fig. 2). The
epithelial cells are organized in tubular units that contain
stem cells somewhere halfway up their length, in the isthmus
zone. Pit cells migrate up from the isthmus towards the
gastric lumen [6], mucous neck cells migrate down towards
the base of the glands, where they transdifferentiate into
chief cells [7], and parietal cells and endocrine cells migrate
towards the gastric lumen and the glands in rodents [8, 9].
PPI treatment reportedly affects the modality of these cells.
The present review is aimed at summarizing the informa-
tion available about the effects of PPI treatment on the
gastric epithelial cell modality.
Changes in Parietal Cells Induced by PPI Treatment
The apical surface of the gastric active parietal cells is
greatly expanded during maximal acid secretion, as com-
pared with that of the resting (inactive) parietal cells [10].
While cimetidine prevented this morphological transition
of the parietal cells, omeprazole failed to prevent such
transition during histamine stimulation [11]. In the last-
mentioned report, administration of omeprazole caused vacu-
olation in approximately 27% of all the parietal cells [11], a
phenomenon that was not seen in the parietal cells of the
control animals treated with histamine alone and seen only
very rarely in the parietal cells of the cimetidine-treated
animals. Ultrastructural examination revealed the vacuoles
may have originated from the secretory canaliculi of the
parietal cells. In another study, the alpha subunit of gastric
H+, K+-ATPase deficient mice showed characteristic parietal
cells with cytoplasmic dilations and large cystic formations
lined by a single layer of a low cuboidal epithelium [12].
KCNQ1 is a K+ channel, mutation of which has been
reported in cases with the cardiac long QT syndrome.
KCNQ1 has been shown to be localized in the tubulovesi-
cles and apical membrane of the parietal cells and to be
colocalized with H+, K+-ATPase in these cells [13]. KCNE2
was identified as the beta subunit of KCNQ1 [14]. KCNQ1
and KCNE2 mediate efflux of K+ ions to balance the influx
of K+ ions influx through the gastric H+, K+-ATPase. Interest-
ingly, KCNQ1-deficient mice [15], KCNE2- deficient mice
[16], as well as the beta subunit of the gastric H+, K+-ATPase
deficient mice exhibited achlorhydria and vacuolization of
the gastric parietal cells. Since the beta subunit of the gastric
H+, K+-ATPase and gastrin double deficient mice did not
exhibit such hyperplasia [17], it is speculated that such
vacuolization might be attributable to secondary hyper-
Fig. 1. Scheme of reaction of PPI and H+, K+-ATPase. PPI convert to tetracyclic sulfonamide and react with cysteine813 in the alpha
subunit of the gastric H+, K+-ATPase.
Fig. 2. Hematoxylin Eosin staining of gastric fundic gland of
mouse. Scale bar indicates 100 µm.Gastric Epithelial Modality and Proton Pump Inhibitor
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gastrinemia.
However, no significant changes of the parietal cell
number or mucosal thickness were observed after short-term
(2–6 weeks) omeprazole treatment in a human study [18].
On the other hand, Driman et al. [19] reported observing
enlarged parietal cells with luminal bulges of cytoplasm,
expanded tubulovesicles, and poorly developed secretory
canaliculi after omeprazole treatment for longer than 12
months in a human study. Although the ultrastructural find-
ings were dissimilar to those in the animal studies reported
previously, this report does suggest that pathological changes
of the parietal cells may be encountered after long-term PPI
treatment. In conclusion, parietal cell enlargement has been
reported following long-term PPI treatment in both animal
and human studies (Fig. 3).
Changes in Chief Cells Induced by PPI Treatment
Sonic hedgehog (Shh) is a morphogen involved in many
aspects of patterning of the gut during embryogenesis and in
gastric fundic gland homeostasis in the adult [20]. Prolonged
colonization by H. pylori has been reported to cause
extension of the inflammation from the antrum to the corpus
of the stomach, with loss of Shh expression which correlated
with the loss of parietal cells [21, 22]. To clarify the expres-
sion of Shh in parietal cell dysfunction not associated with
inflammation, we used H2R-deficient (H2R-null) mice and
an acid exposure model [23]. To study the effects of acid
exposure, HCl solution was administered to the animals. The
H2R-null mice exhibited higher gastric pH, reduced Shh
expression and impaired mucous neck-to-zymogenic cell
differentiation. Furthermore, the expression level of Shh
increased in the presence of gastric acid and showed a
significant correlation with the gastric surface pH. These
results suggest that suppressed gastric acid secretion alone
may be sufficient to down-regulate Shh expression.
Kakei  et al. [24] reported that 4 weeks treatment with
omeprazole induced a marked decrease in the number of
chief cells in the gastric mucosa with a concomitant increase
in the number of immature pepsinogen-producing cells
expressing class III mucin. These changes were associated
with decrease to 60% and 10% of the control values in the
mucosal levels of pepsinogen and its mRNA, respectively.
Moreover, cell proliferation assays have revealed that
the percentage of bromodeoxyuridine-labeled cells was
increased by omeprazole. These alterations were reversed
by discontinuation of the omeprazole treatment, suggesting
that omeprazole treatment for 4 weeks induced a reversible
change in the cell proliferation and de-differentiation of the
gastric epithelial cells.
Changes in the Endocrine Cells Associated with PPI
Treatment
Endocrine cells in the oxyntic mucosa are composed of
ECL, D, enterochromaffin (EC), and A-like cells, as identi-
Fig. 3. Scheme of changes of gastric epithelial cell in the bottom of gastric gland by PPI treatment. PPI treatment caused enlargement
of parietal cell and ECL cell, it decreased number of chief cells. Then, gastric gland became hyperplastic.T. Masaoka et al.
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fied based on ultrastructural and immunohistochemical cri-
teria [25].The relative percentages of these four cells in the
human oxyntic glands are 30% for ECL cells, 20% for A-
like cells, 22% for D cells, and 7% for EC cells [26]. D cells
which produce somatostatin are located mainly in the
pyloric antrum.
ECL cells have been reported to increase in size after 2
weeks of omeprazole treatment in rodents [27]. Lamberts
et al. [28] reported the doubling of the mean argyrophil cell
density after long-term (6–84) omeprazole treatment in
patients with gastric ulcer. Eissele et al. [ 29] reported a
statistically significant increase in the fundic gland argyro-
phil cell density after long-term (up to 5 years) lansoprazole
treatment in patients with peptic disorders. In their paper,
they reported detecting argyrophil cell hyperplasia in 2.6%
of the patients before lansoprazole treatment and in 29.2%
of the patients after long-term lansoprazole treatment. We
previously reported the pH-independent effects of PPI such
as lansoprazole on cell restitution in vitro; treatment with
lansoprazole significantly promoted the cell restitution rate
after wounding, while the addition of an MEK inhibitor
significantly attenuated the cell restitution rate in the lanso-
prazole groups, suggesting that the mechanism of cell pro-
liferation and migration promoted by lansoprazole might
involve the activation of p44/p42 MAPK [30]. Such hyper-
plasia might be attributable to promoted cell proliferation.
In 1983, all of the omeprazole studies in humans were
stopped because rodents given omeprazole developed
gastric endocrine cell hyperplasia and carcinoid tumors [31].
Maton  et al. reported that none of their patients with
Zollinger-Ellison syndrome who were administered omepra-
zole for up to 3 years developed any significant changes in
the percentage of argyrophil cells, carcinoid tumors, and
changes in the serum concentrations of gastrin [32]. Jensen
et al. reported that none of the 21 patients with Zollinger-
Ellison syndrome who were administered lansoprazole for a
mean of 31 months developed gastric carcinoid tumors [33].
These studies on patients with Zollinger-Ellison syndrome
are of great significance in relation to the safety concerns of
PPIs in terms of gastric carcinoid development.
A-like cells are major endocrine cells of the oxyntic
mucosa of both rats and humans. A-like cells have been
identified in the oxyntic mucosa based on ultrastructural and
immunohistochemical criteria [25]. Recently, their hormonal
product had been clarified as ghrelin [34]. Ghrelin, a peptide
composed of 28 amino acids, has been shown to be a natural
ligand of the growth hormone secretagogue receptor. Ghrelin
is secreted from A-like cells in the gastric fundus [35].
Under physiological conditions, ghrelin stimulates not only
GH release, but also food intake, cardiac out put, gastric
motility and acid secretion [36]. Cui et al. [ 37] reported
that omeprazole treatment for 11 weeks induced hyper-
trophy of the oxyntic mucosa with the hyperplasia of the
ECL, but not A-like cells. Thus, PPI treatment might not
affect the modality of A-like cells. On the other hand, H.
pylori infection modified the dynamics of ghrelin [38, 39].
Atrophic Gastritis and PPI Treatment
To evaluate whether acid suppression might increase the
risk of atrophic gastritis, Kuipers et al. [ 40] compared
patients with reflux esophagitis treated by fundoplication or
omeprazole. In the cohort treated by fundoplication, none of
the subjects showed development of atrophic gastritis. On
the other hand, in the cohorts treated with omeprazole,
development of atrophic gastritis was observed in 30.5% of
the H. pylori infected patients. These findings suggest that
omeprazole treatment might increase the risk of atrophic
gastritis in patients with H. pylori infected reflux esoph-
agitis. However, Lundell et al. [41] did not confirm these
results. Then, Kuipers et al. [42] performed a prospective
controlled trial to evaluate the effects of H. pylori eradica-
tion therapy. In their study, H. pylori eradication therapy
eliminated gastric mucosal inflammation and induces regres-
sion of corpus gland atrophy. They concluded by recom-
mending H. pylori eradication therapy in GERD patients
receiving long-term acid suppressive therapy.
To clarify whether acid-suppressive therapy might pro-
mote corpus gastritis in patients with H. pylori infection,
Uemura et al. [43] examined H. pylori-positive patients who
were treated with either omeprazole alone or with omepra-
zole for primary therapy, followed by famotidine for mainte-
nance therapy for 3 years in Japan. In their report, no in-
crease in the frequency of endoscopically assessed mucosal
atrophy was observed during the observation period. These
differences might be attributable to the method of the assess-
ment of atrophy [43] or racial differences.
Fundic-gland Type Polyps and PPI Treatment
Jalving et al. studied whether proton pump inhibitor use
might lead to the development of fundic gland type polyps
(FGPs) [44]. In their study, the presence of FGPs was as-
sessed in patients receiving a PPI treatment. Among the 599
patients who participated, 322 patients were receiving PPI
treatment, and 107 of these patients had fundic gland polyps.
Long-term PPI treatment was associated with both a large
proportional cystic area and parietal cell hyperplasia and
protrusion. Vieth et al. retrospectively compared the
frequency of FGPs in 2,251 patients without H. pylori
infection who received PPI treatment (at least 4 weeks) with
that in a control group of 28,096 patients without H. pylori
infection and without PPI treatment. FGPs were identified at
an identical frequency in both groups, indicating the unclear
pathogenetic relationship between PPI treatment and FGPs
[45].Gastric Epithelial Modality and Proton Pump Inhibitor
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Epilogue
Although, long-term PPI treatment was associated with
enlargement of the parietal cell and ECL cells, the number of
chief cells decreased and these drugs had no effect on the A-
like cells. Although the development of gastric carcinoid
tumors has been reported following chronic PPI treatment in
animals, this has not been observed until now in humans.
Clarification of the effect of PPIs on the formation of FGPs
and the development of atrophic gastritis requires further
investigation.
Abbreviations
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